ARO-HBV
Hepatitis B
Phase 1Active
Key Facts
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology through their Targeted RNAi Molecule (TRiM™) platform to develop therapeutics that silence genes causing disease. With over a decade of experience in RNAi-based therapies, the company has advanced multiple programs across cardiometabolic, liver, and pulmonary diseases. Their lead asset Plozasiran has achieved commercial approval for FCS and is advancing in Phase 3 trials for severe hypertriglyceridemia, demonstrating the platform's potential to address significant unmet medical needs.
View full company profileTherapeutic Areas
Other Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| GS-5245 | Gilead Sciences | Phase 2 |
| ABX196 | Abivax | Preclinical |